Press release Communiqué de presse
Press release Communiqué de presse
June 23, 2003 23 June, 2003
Pheromone Sciences Issued U.S. Patent on Pheromone's Sensing and Reporting Technology
Toronto, Ontario (July 23, 2003) --
Sciences Corp (TSX-V: PHS), a developer of
prediction medical devices for both human and
animal applications, today announced that the
Office has issued patent No. 6,592,529 covering
Pheromone's sensing and reporting technology
early prediction of ovulation for female
including humans, using innovative
sweat ion concentrations. Fertility prediction and
is of daily interest to the lives of millions of
the United States.
"This patent will serve as a valuable asset as we work through licensing opportunities with potential strategic partners in both the human and large animal marketplaces", remarked Christopher Neuman, President and CEO of Pheromone Sciences. "The patent recognizes the propriety position of Pheromone's unique technology for ovulation detection through the non invasive measurement of sweat ion constituents and demonstrates our ongoing commitment to the development of a comprehensive intellectual property portfolio."
The patent is also applicable to the Company's veterinary program. Within the North American dairy industry, it is estimated that about 2 million dairy cows are monitored for their ovulation date at any given point in time as a precursor to artificial insemination procedures being provided to these cattle.
About Pheromone Sciences Corp:
PHEROMONE SCIENCES is a biotechnology and medical diagnostics & device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.
PHEROMONE SCIENCES has capitalized on its potentially breakthrough sensing and reporting technology initially through the development of two products:
- FertilitÃ?Â©-OVÃ¢ï¿½Â¢ monitor, a non- invasive fertility cycle monitoring device for the medical professional & consumer market which provides up to 4 days advance notice of ovulation and thereby improving the probability and speed of conception. The product is approved for marketing in the USA, Canada and Western Europe and the company is currently in discussions for marketing and sales partnerships to bring this technology to the consumer.
- The company is currently in feasibility studies that may in the future bring this technology to the dairy industry.
Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.
Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.
Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.
INVESTOR CONTACT Lorne Woods 1-(800) 937-3095 firstname.lastname@example.org www.pheromonesciences.com